US EditionDrugmakers brace for Europe pricing fight after Trump's US price-cut deals
European governments plan tougher drug price negotiations in 2026 after U.S. price cuts under Trump, risking delayed launches and reduced patient access, experts say.
- This coming week at the J.P. Morgan Healthcare Conference in San Francisco, global drugmakers face a 2026 battle to secure higher European prices after cutting U.S. prices last year under President Donald Trump.
- Last year, fourteen major pharmaceutical companies agreed to cut prices for some Medicaid and cash-paying patients and to tie U.S. launch prices to those in other wealthy countries, while the U.S.-UK deal granted Britain tariff relief for a 25% price increase.
- Tougher talks may prompt companies to delay European launches, with some treatments priced over $1.5 million per course including Johnson & Johnson's Inlexzo, raising European patients' access concerns.
- Analysts cautioned that political pressure may not quickly translate into higher European prices, though shares of most drugmakers rose as investors downplayed price cut impacts, Linden Thomson said.
- Bayer's Sebastian Guth notes a wide access gap between the U.S. and Europe, saying `If you look at innovative medicines that were launched and approved over the past 10 years, Americans have access to 80% of those while Europeans have access to less than 50%`.
22 Articles
22 Articles
Drugmakers brace for Europe pricing fight after Trump's US price-cut deals
Global drugmakers face a battle in 2026 to secure higher prices for their prescription medicines in Europe after agreeing to cut U.S. pricing last year under pressure from President Donald Trump.
Trump has announced deals with drugmakers to cut costs. Will they save people money?
President Donald Trump’s deals with pharmaceutical companies are likely to have only a limited impact on Americans’ drug spending, experts say. Since Sept. 30, the Trump administration has struck deals with 14 drugmakers in exchange for tariff relief, according to the White House. The agreements — which haven’t gone into effect yet — adopt a “most favored nation” pricing model. They tie U.S. prices to those paid in other wealthy countries, lower…
Donald Trump has chosen Switzerland as a reference country for drug prices. The impact could be far-reaching.
President Donald Trump’s agreements with pharmaceutical companies will likely have a limited impact on Americans’ spending on drugs, experts say. Since September 30, the Trump administration has reached agreements with 14 drug manufacturers in exchange for tariff relief, according to the White House. The agreements, which have not yet entered into force, adopt a “most favoured nation” price model. They tie prices in the United States to those pa…
Telemundo Las Vegas
President Donald Trump’s agreements with pharmaceutical companies will likely have a limited impact on Americans’ spending on drugs, experts say. Since September 30, the Trump administration has reached agreements with 14 drug manufacturers in exchange for tariff relief, according to the White House. The agreements, which have not yet entered into force, adopt a “most favoured nation” price model. They tie prices in the United States to those pa…
Coverage Details
Bias Distribution
- 57% of the sources lean Left
Factuality
To view factuality data please Upgrade to Premium
